Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report)'s share price gapped down prior to trading on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $23.83, but opened at $22.91. Kestra Medical Technologies shares last traded at $23.34, with a volume of 29,702 shares trading hands.
The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.61). During the same period in the previous year, the company earned ($1.18) earnings per share.
Analysts Set New Price Targets
KMTS has been the subject of several recent analyst reports. Stifel Nicolaus initiated coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They issued a "buy" rating and a $28.00 target price for the company. Wolfe Research started coverage on Kestra Medical Technologies in a research note on Monday, March 31st. They issued an "outperform" rating and a $29.00 price target for the company. Wells Fargo & Company began coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued an "overweight" rating and a $28.00 price objective for the company. The Goldman Sachs Group lowered their price objective on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Piper Sandler assumed coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $27.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $27.50.
Get Our Latest Stock Analysis on KMTS
Kestra Medical Technologies Stock Down 0.3 %
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Recommended Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
